Comparative analysis of streptozocin-based regimen and capecitabine-temozolomide therapy in advanced pancreatic neuroendocrine neoplasms: influence of tumor grade and Ki-67 index.

In the NET-G3 subgroup, the median PFS was 8.6 months (95% CI: 0.0–24.3) for the STZ group and 19.7 months (95% CI: 7.5–31.8) for the CAPTEM group, although it did not reach statistical significance ( p = 0.217; Figure 3(c) ).

also in 111,027 other papers